drugset
drugset / Trial / NCT00483366

Imatinib Mesylate, Gemcitabine, and Capecitabine in Treating Patients With Advanced Solid Tumors

NCT00483366 ↗

Phase 1 Completed 13 enrolled University of Nebraska National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving imatinib mesylate together with gemcitabine and capecitabine may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of gemcitabine and capecitabine when given together with imatinib mesylate in treating patients with advanced solid tumors.

Timeline

Start
2006-08-15
Primary completion
2009-01-30
Completion
2011-03-29

Drugs

EvaluationDrugModalityDoseRoute
Subject Capecitabine Small molecule 400 mg/m2 Oral
Subject Capecitabine Small molecule 500 mg/m2 Oral
Subject Capecitabine Small molecule 600 mg/m2 Oral
Subject Capecitabine Small molecule 725 mg/m2 Oral
Subject Capecitabine Small molecule 850 mg/m2 Oral
Subject Gemcitabine Small molecule 400 mg/m2 Intravenous
Subject Gemcitabine Small molecule 450 mg/m2 Intravenous
Subject Gemcitabine Small molecule 550 mg/m2 Intravenous
Subject Gemcitabine Small molecule 675 mg/m2 Intravenous
Subject Gemcitabine Small molecule 825 mg/m2 Intravenous
Subject Gemcitabine Small molecule 1000 mg/m2 Intravenous
Background Imatinib Small molecule 400 mg Oral

Indications

cancer of unknown primary site